Supernus stock surges on FDA approval
Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) climbed 5.5% Tuesday as the U.S. Food and Drug Administration approved ...
Nasdaq6d
FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases
Allogene Therapeutics, Inc. ALLO announced that the FDA has cleared its investigational ... the average surprise being 172.72%. 7 Best Stocks for the Next 30 Days Just released: Experts distill ...
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
ONAPGOis the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s ...
FDA recall for broccoli sold at Walmart
It could be contaminated with Listeria.
Supernus announces FDA approval of ONAPGO
Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, approved ONAPGO injection, formerly known as ...
Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025
The healthcare sector is staging a comeback so far in 2025 after two years of underperformance. These stocks could get even ...
Biotech Stocks Facing FDA Decision In February 2025
February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...
Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?
Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...
Supernus stock climbs 5% on FDA approval of Onapgo
Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) rose 5% Tuesday morning on news the FDA has approved its wearable treatment device Onapgo, formerly known as SPN-830, for the treatment of patients ...
NeuroOne regains Nasdaq compliance with share price
Technologies Corporation (NASDAQ:NMTC), a medical technology firm specializing in neurological surgical solutions with a market capitalization of $32 million, has recently announced it has met ...
HCW Biologics Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial
Wong, Founder and CEO of HCW Biologics, commented, “The FDA’s clearance to initiate our first-in-human clinical trial for HCW9302 brings us one step closer to advancing a potentially transformative ...